Willemse P H, Sleijfer D T, Schraffordt Koops H, De Bruijn H W, Oosterhuis J W, Brouwers T M, Ockhuizen T, Marrink J
Oncodev Biol Med. 1981;2(1-2):129-34.
The decline of serum levels of AFP or HCG in 26 patients with disseminated non-seminomatous germ cell tumors during chemotherapy showed two different patterns: a linear decline or an increasing apparent half life (AHL). The initial AFP half life in 13 patients with a linear decline was 7.2 +/- 1.8 days, and did not differ from the initial half life in 5 patients with a curvi-linear pattern. HCG half life was 3.0 +/- 0.5 days in 10 patients with a linear AHL, and was not different from the initial half life in 6 patients with delayed marker disappearance. Based on the half life pattern of AFP or HCG the result of chemotherapy was predicted. When AFP or HCG showed a linear decline, all viable tumor appeared to be eliminated in 38 and 40% respectively of the patients. An increasing AHL indicated the presence of active tumor, mostly mature teratoma, in 60% of the patients with AFP and in 83% of the patients with HCG. Thus, the pattern of AFP or HCG half life does not predict the eventual outcome of chemotherapy with certainty.
26例播散性非精原细胞瘤性生殖细胞肿瘤患者化疗期间血清甲胎蛋白（AFP）或人绒毛膜促性腺激素（HCG）水平下降呈现两种不同模式：直线下降或表观半衰期（AHL）延长。13例呈直线下降的患者初始AFP半衰期为7.2±1.8天，与5例呈曲线模式患者的初始半衰期无差异。10例呈直线AHL的患者HCG半衰期为3.0±0.5天，与6例标志物消失延迟患者的初始半衰期无差异。根据AFP或HCG的半衰期模式对化疗结果进行预测。当AFP或HCG呈直线下降时，分别有38%和40%的患者所有存活肿瘤似乎被清除。AHL延长表明60%的AFP患者和83%的HCG患者存在活性肿瘤，主要为成熟畸胎瘤。因此，AFP或HCG半衰期模式并不能确切预测化疗的最终结果。
